Sweden

Sweden

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.54 (0.46 - 0.62) 2019 Modelled IHME
0.55 (0.47 - 0.63) 2018 Modelled IHME
0.55 (0.48 - 0.63) 2017 Modelled IHME
0.55 (0.48 - 0.63) 2016 Modelled IHME
0.55 (0.47 - 0.63) 2015 Modelled IHME
0.55 (0.48 - 0.63) 2014 Modelled IHME
0.56 (0.48 - 0.64) 2013 Modelled IHME
0.56 (0.48 - 0.64) 2012 Modelled IHME
0.56 (0.48 - 0.64) 2011 Modelled IHME
0.56 (0.48 - 0.64) 2010 Modelled IHME
0.56 (0.48 - 0.64) 2009 Modelled IHME
0.56 (0.48 - 0.64) 2008 Modelled IHME
0.56 (0.48 - 0.64) 2007 Modelled IHME
0.56 (0.48 - 0.63) 2006 Modelled IHME
0.55 (0.48 - 0.63) 2005 Modelled IHME
0.56 (0.48 - 0.63) 2004 Modelled IHME
0.56 (0.48 - 0.63) 2003 Modelled IHME
0.56 (0.48 - 0.63) 2002 Modelled IHME
0.56 (0.48 - 0.64) 2001 Modelled IHME
0.56 (0.48 - 0.64) 2000 Modelled IHME
0.56 (0.48 - 0.64) 1999 Modelled IHME
0.56 (0.49 - 0.64) 1998 Modelled IHME
0.56 (0.49 - 0.65) 1997 Modelled IHME
0.57 (0.49 - 0.65) 1996 Modelled IHME
0.57 (0.49 - 0.65) 1995 Modelled IHME
0.57 (0.49 - 0.66) 1994 Modelled IHME
0.57 (0.49 - 0.66) 1993 Modelled IHME
0.58 (0.49 - 0.66) 1992 Modelled IHME
0.58 (0.49 - 0.66) 1991 Modelled IHME
0.58 (0.49 - 0.66) 1990 Modelled IHME
0.63 (0.47 - 0.85) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.08 (0.06 - 0.10) 2019 Modelled IHME
0.08 (0.06 - 0.10) 2018 Modelled IHME
0.09 (0.07 - 0.11) 2017 Modelled IHME
0.11 (0.08 - 0.14) 2016 Modelled IHME
0.13 (0.10 - 0.17) 2015 Modelled IHME
0.17 (0.12 - 0.21) 2014 Modelled IHME
0.2 (0.15 - 0.26) 2013 Modelled IHME
0.24 (0.18 - 0.31) 2012 Modelled IHME
0.27 (0.21 - 0.35) 2011 Modelled IHME
0.28 (0.22 - 0.36) 2010 Modelled IHME
0.28 (0.22 - 0.36) 2009 Modelled IHME
0.28 (0.21 - 0.35) 2008 Modelled IHME
0.27 (0.20 - 0.34) 2007 Modelled IHME
0.27 (0.20 - 0.34) 2006 Modelled IHME
0.26 (0.19 - 0.34) 2005 Modelled IHME
0.27 (0.19 - 0.34) 2004 Modelled IHME
0.27 (0.19 - 0.34) 2003 Modelled IHME
0.27 (0.20 - 0.34) 2002 Modelled IHME
0.27 (0.20 - 0.34) 2001 Modelled IHME
0.27 (0.20 - 0.34) 2000 Modelled IHME
0.28 (0.21 - 0.35) 1999 Modelled IHME
0.28 (0.21 - 0.36) 1998 Modelled IHME
0.28 (0.21 - 0.37) 1997 Modelled IHME
0.29 (0.22 - 0.38) 1996 Modelled IHME
0.29 (0.22 - 0.38) 1995 Modelled IHME
0.29 (0.22 - 0.38) 1994 Modelled IHME
0.29 (0.21 - 0.38) 1993 Modelled IHME
0.29 (0.21 - 0.38) 1992 Modelled IHME
0.28 (0.20 - 0.37) 1991 Modelled IHME
0.28 (0.19 - 0.37) 1990 Modelled IHME
0.32 (0.23 - 0.46) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
5 (4 - 7) 2019 Modelled IHME
5 (4 - 7) 2018 Modelled IHME
5 (4 - 7) 2017 Modelled IHME
5 (4 - 7) 2016 Modelled IHME
5 (4 - 7) 2015 Modelled IHME
5 (4 - 7) 2014 Modelled IHME
5 (4 - 7) 2013 Modelled IHME
5 (4 - 7) 2012 Modelled IHME
6 (4 - 7) 2011 Modelled IHME
6 (4 - 7) 2010 Modelled IHME
6 (4 - 7) 2009 Modelled IHME
6 (4 - 7) 2008 Modelled IHME
6 (4 - 7) 2007 Modelled IHME
5 (4 - 7) 2006 Modelled IHME
5 (4 - 7) 2005 Modelled IHME
5 (4 - 7) 2004 Modelled IHME
5 (4 - 7) 2003 Modelled IHME
5 (4 - 7) 2002 Modelled IHME
5 (4 - 7) 2001 Modelled IHME
5 (4 - 7) 2000 Modelled IHME
5 (4 - 7) 1999 Modelled IHME
5 (4 - 7) 1998 Modelled IHME
5 (4 - 7) 1997 Modelled IHME
5 (4 - 7) 1996 Modelled IHME
5 (4 - 7) 1995 Modelled IHME
5 (4 - 7) 1994 Modelled IHME
5 (4 - 7) 1993 Modelled IHME
5 (4 - 7) 1992 Modelled IHME
5 (4 - 7) 1991 Modelled IHME
6 (4 - 7) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
92 2018 Survey/reported WHO/UNICEF
76 2017 Survey/reported WHO/UNICEF
67 2016 Survey/reported WHO/UNICEF
53 2015 Survey/reported WHO/UNICEF
42 2014 Survey/reported WHO/UNICEF
35 2013 Survey/reported WHO/UNICEF
30 2012 Survey/reported WHO/UNICEF
29 2011 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
34 (7 - 161) 2015 Survey/reported Larney S et al, 2017
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.78 (0.63 - 0.96) 2019 Modelled IHME
0.78 (0.63 - 0.96) 2018 Modelled IHME
0.78 (0.63 - 0.95) 2017 Modelled IHME
0.77 (0.62 - 0.94) 2016 Modelled IHME
0.76 (0.61 - 0.93) 2015 Modelled IHME
0.76 (0.61 - 0.94) 2014 Modelled IHME
0.76 (0.61 - 0.94) 2013 Modelled IHME
0.77 (0.62 - 0.94) 2012 Modelled IHME
0.77 (0.62 - 0.94) 2011 Modelled IHME
0.77 (0.62 - 0.95) 2010 Modelled IHME
0.77 (0.62 - 0.94) 2009 Modelled IHME
0.76 (0.61 - 0.94) 2008 Modelled IHME
0.76 (0.61 - 0.93) 2007 Modelled IHME
0.76 (0.61 - 0.93) 2006 Modelled IHME
0.75 (0.61 - 0.92) 2005 Modelled IHME
0.75 (0.61 - 0.92) 2004 Modelled IHME
0.75 (0.61 - 0.92) 2003 Modelled IHME
0.75 (0.60 - 0.92) 2002 Modelled IHME
0.75 (0.60 - 0.92) 2001 Modelled IHME
0.75 (0.60 - 0.91) 2000 Modelled IHME
0.75 (0.60 - 0.91) 1999 Modelled IHME
0.75 (0.60 - 0.91) 1998 Modelled IHME
0.75 (0.60 - 0.91) 1997 Modelled IHME
0.75 (0.61 - 0.91) 1996 Modelled IHME
0.75 (0.61 - 0.91) 1995 Modelled IHME
0.75 (0.61 - 0.91) 1994 Modelled IHME
0.75 (0.61 - 0.92) 1993 Modelled IHME
0.76 (0.61 - 0.92) 1992 Modelled IHME
0.76 (0.61 - 0.92) 1991 Modelled IHME
0.77 (0.62 - 0.93) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.7 (0.50 - 0.70) 2014 Modelled Gower et al, 2014
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
0.6 (0.20 - 1.30) 2013 Survey/reported Blaxhult A et al , 2013
People who inject drugs (PWID)
Download
Value (%) Year Type Source
81.7 (79.60 - 83.60) 2014 Survey/reported Fraser H et al, 2016

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
38 (32 - 43) 2019 Modelled IHME
38 (32 - 44) 2018 Modelled IHME
38 (33 - 44) 2017 Modelled IHME
38 (32 - 44) 2016 Modelled IHME
38 (32 - 44) 2015 Modelled IHME
38 (32 - 44) 2014 Modelled IHME
38 (33 - 44) 2013 Modelled IHME
38 (33 - 44) 2012 Modelled IHME
39 (33 - 44) 2011 Modelled IHME
39 (33 - 44) 2010 Modelled IHME
39 (33 - 44) 2009 Modelled IHME
39 (34 - 45) 2008 Modelled IHME
39 (34 - 45) 2007 Modelled IHME
40 (34 - 45) 2006 Modelled IHME
40 (34 - 45) 2005 Modelled IHME
39 (34 - 45) 2004 Modelled IHME
40 (34 - 45) 2003 Modelled IHME
40 (34 - 45) 2002 Modelled IHME
40 (34 - 46) 2001 Modelled IHME
40 (34 - 46) 2000 Modelled IHME
40 (34 - 46) 1999 Modelled IHME
41 (35 - 46) 1998 Modelled IHME
41 (35 - 46) 1997 Modelled IHME
41 (35 - 46) 1996 Modelled IHME
41 (35 - 46) 1995 Modelled IHME
41 (35 - 47) 1994 Modelled IHME
41 (35 - 47) 1993 Modelled IHME
41 (35 - 47) 1992 Modelled IHME
41 (35 - 47) 1991 Modelled IHME
41 (35 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (7 - 161) 2015 Survey/reported Larney S et al, 2017
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.54 (%)
2019
(0.46 - 0.62(%))
IHME
HCV (RNA/cAg+)
0.78 (%)
2019
(0.63 - 0.96(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
129
2019
(110 - 151)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
401
2019
(348 - 456)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.08 (%)
2019, latest modelled
(0.06 - 0.10(%))
IHME

Prevalence PWID

HCV
81.70 (%)
2014, survey/surveillance
(79.60 - 83.60(%))
Fraser H et al, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
34
2015
(7 - 161)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources